NASDAQ:AVDL Avadel Pharmaceuticals (AVDL) Stock Price, News & Analysis $10.11 -0.20 (-1.94%) (As of 11:14 AM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Avadel Pharmaceuticals Stock (NASDAQ:AVDL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Avadel Pharmaceuticals alerts:Sign Up Key Stats Today's Range$9.97▼$10.4550-Day Range$9.94▼$16.3052-Week Range$9.41▼$19.09Volume132,139 shsAverage Volume1.19 million shsMarket Capitalization$974.22 millionP/E RatioN/ADividend YieldN/APrice Target$24.43Consensus RatingBuy Company OverviewAvadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Read More… Avadel Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks54th Percentile Overall ScoreAVDL MarketRank™: Avadel Pharmaceuticals scored higher than 54% of companies evaluated by MarketBeat, and ranked 503rd out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAvadel Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAvadel Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Avadel Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Avadel Pharmaceuticals are expected to grow in the coming year, from ($0.48) to $0.53 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avadel Pharmaceuticals is -13.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avadel Pharmaceuticals is -13.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvadel Pharmaceuticals has a P/B Ratio of 10.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.16% of the outstanding shares of Avadel Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAvadel Pharmaceuticals has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Avadel Pharmaceuticals has recently increased by 11.12%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAvadel Pharmaceuticals does not currently pay a dividend.Dividend GrowthAvadel Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.16% of the outstanding shares of Avadel Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAvadel Pharmaceuticals has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Avadel Pharmaceuticals has recently increased by 11.12%, indicating that investor sentiment is decreasing significantly. News and Social Media2.9 / 5News Sentiment1.27 News SentimentAvadel Pharmaceuticals has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Avadel Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 7 people have searched for AVDL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Avadel Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $406,313.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.80% of the stock of Avadel Pharmaceuticals is held by insiders.Percentage Held by Institutions69.19% of the stock of Avadel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Avadel Pharmaceuticals' insider trading history. Receive AVDL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AVDL Stock News HeadlinesInsider Buying: Avadel Pharmaceuticals plc (NASDAQ:AVDL) CFO Purchases 2,300 Shares of StockDecember 17, 2024 | insidertrades.comAvadel Pharmaceuticals plc (NASDAQ:AVDL) CFO Thomas S. Mchugh Purchases 5,000 SharesDecember 13, 2024 | insidertrades.comYour chance to get on the next “60-Second Trade”Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!December 23, 2024 | WealthPress (Ad)Linda Palczuk Acquires 3,000 Shares of Avadel Pharmaceuticals plc (NASDAQ:AVDL) StockDecember 11, 2024 | insidertrades.comAvadel Pharmaceuticals PLC AVDLDecember 20 at 9:29 PM | morningstar.comLeerink Partners Remains a Buy on Avadel Pharmaceuticals (AVDL)December 18, 2024 | markets.businessinsider.comAvadel Pharmaceuticals (NASDAQ:AVDL) Trading Up 4.7% Following Insider Buying ActivityDecember 13, 2024 | americanbankingnews.comIndependent Non-Executive Chairman of the Board of Avadel Pharmaceuticals Picks Up 16% More StockDecember 12, 2024 | finance.yahoo.comSee More Headlines AVDL Stock Analysis - Frequently Asked Questions How have AVDL shares performed this year? Avadel Pharmaceuticals' stock was trading at $14.12 at the beginning of 2024. Since then, AVDL shares have decreased by 27.0% and is now trading at $10.31. View the best growth stocks for 2024 here. How were Avadel Pharmaceuticals' earnings last quarter? Avadel Pharmaceuticals plc (NASDAQ:AVDL) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.03. The business's revenue was up 624.6% on a year-over-year basis. Who are Avadel Pharmaceuticals' major shareholders? Top institutional shareholders of Avadel Pharmaceuticals include Janus Henderson Group PLC (13.84%), Braidwell LP (3.52%), Wealth Effects LLC (2.32%) and Vestal Point Capital LP. Insiders that own company stock include Eric J Ende, Thomas S Mchugh, Geoffrey Michael Glass, Mark Anthony Mccamish, Linda Palczuk and Gregory J Divis. View institutional ownership trends. How do I buy shares of Avadel Pharmaceuticals? Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Avadel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Avadel Pharmaceuticals investors own include Advanced Micro Devices (AMD), Bank of America (BAC), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Cisco Systems (CSCO) and Netflix (NFLX). Company Calendar Last Earnings11/12/2024Today12/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AVDL CUSIPN/A CIK1012477 Webwww.avadel.com Phone(531) 901-5201Fax353-1526-1077Employees154Year Founded2015Price Target and Rating Average Stock Price Target$24.43 High Stock Price Target$30.00 Low Stock Price Target$21.00 Potential Upside/Downside+136.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-160,280,000.00 Net Margins-52.53% Pretax Margin-52.84% Return on Equity-93.34% Return on Assets-44.77% Debt Debt-to-Equity RatioN/A Current Ratio2.97 Quick Ratio2.60 Sales & Book Value Annual Sales$138.16 million Price / Sales7.19 Cash FlowN/A Price / Cash FlowN/A Book Value$0.98 per share Price / Book10.52Miscellaneous Outstanding Shares96,362,000Free Float91,737,000Market Cap$993.49 million OptionableOptionable Beta1.32 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:AVDL) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avadel Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Avadel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.